Stock Scorer

Pediatrix Medical Group, Inc. (MD)

Pediatrix Medical Group, Inc. reported revenue of 487.8M USD for the quarter ending 30 June 2026, up 4.0% from 468.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 487.8M +4.0%
Operating Income Q2 '26 · ending 30 June 2026 56.9M -4.9%
Net Income Q2 '26 · ending 30 June 2026 39.8M +1.5%
Operating Cash Flow Q2 '26 · ending 30 June 2026 125.3M -8.6%
Free Cash Flow Q2 '26 · ending 30 June 2026 123.9M -6.6%
Shares Outstanding Q2 '26 · ending 30 June 2026 81.4M -4.7%
EPS Q2 '26 · ending 30 June 2026 2.09 +60.8%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1.9B208.8M165.4M252.6M
20242024-12-31 2B-68.7M-99.1M184.6M
20232023-12-31 2B7.3M-60.4M104M
20222022-12-31 2B172.7M66.3M137.2M
20212021-12-31 1.9B202.9M131M44.5M
20202020-12-31 1.7B98.1M-796.5M175.8M
20192019-12-31 1.8B171.8M-1.5B338.4M
20182018-12-31 1.7B248.4M268.6M296.6M
20172017-12-31 3.3B454.9M320.4M485.2M
20162016-12-31 3.2B571.7M324.9M404.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30487.8M
Q1 '262026-03-31476.2M
Q4 '252025-12-31493.8M
Q3 '252025-09-30492.9M
Q2 '252025-06-30468.8M
Q1 '252025-03-31458.4M
Q4 '242024-12-31502.4M
Q3 '242024-09-30511.2M
Q2 '242024-06-30504.3M
Q1 '242024-03-31495.1M
Q4 '232023-12-31496.4M
Q3 '232023-09-30506.6M
Q2 '232023-06-30500.6M
Q1 '232023-03-31491M
Q4 '222022-12-31513.8M
Q3 '222022-09-30489.9M
Q2 '222022-06-30486M
Q1 '222022-03-31482.2M
Q4 '212021-12-31498.5M
Q3 '212021-09-30492.9M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-3056.9M
Q1 '262026-03-3141.7M
Q4 '252025-12-3148.8M
Q3 '252025-09-3068.1M
Q2 '252025-06-3059.9M
Q1 '252025-03-3132.1M
Q4 '242024-12-3139.3M
Q3 '242024-09-3033.8M
Q2 '242024-06-30-157.7M
Q1 '242024-03-3115.9M
Q3 '232023-09-3040.3M
Q2 '232023-06-3048.5M
Q1 '232023-03-3130M
Q4 '222022-12-3136M
Q3 '222022-09-3047.4M
Q2 '222022-06-3050.2M
Q1 '222022-03-3139.1M
Q4 '212021-12-3168M
Q3 '212021-09-3058.8M
Q2 '212021-06-3050M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3039.8M
Q1 '262026-03-3129.6M
Q4 '252025-12-3133.7M
Q3 '252025-09-3071.7M
Q2 '252025-06-3039.3M
Q1 '252025-03-3120.7M
Q4 '242024-12-3130.5M
Q3 '242024-09-3019.4M
Q2 '242024-06-30-153M
Q1 '242024-03-314M
Q3 '232023-09-3021.4M
Q2 '232023-06-3028.3M
Q1 '232023-03-3114.2M
Q4 '222022-12-3129.7M
Q3 '222022-09-3030.7M
Q2 '222022-06-3027.1M
Q1 '222022-03-31-21.2M
Q4 '212021-12-3147.5M
Q3 '212021-09-3030.8M
Q2 '212021-06-3035M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30125.3M
Q1 '262026-03-31-129.8M
Q4 '252025-12-31114.1M
Q3 '252025-09-30137.3M
Q2 '252025-06-30137.2M
Q1 '252025-03-31-117.5M
Q4 '242024-12-31133M
Q3 '242024-09-3091.8M
Q2 '242024-06-30107M
Q1 '242024-03-31-125.2M
Q4 '232023-12-3169.2M
Q3 '232023-09-3079.9M
Q2 '232023-06-3089.1M
Q1 '232023-03-31-100.9M
Q4 '222022-12-3198.7M
Q3 '222022-09-3083.3M
Q2 '222022-06-3082.4M
Q1 '222022-03-31-97.5M
Q4 '212021-12-3175M
Q3 '212021-09-3061.1M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30123.9M
Q1 '262026-03-31-136.1M
Q4 '252025-12-31108.8M
Q3 '252025-09-30131.9M
Q2 '252025-06-30132.7M
Q1 '252025-03-31-120.8M
Q4 '242024-12-31129.6M
Q3 '242024-09-3085.5M
Q2 '242024-06-30100M
Q1 '242024-03-31-130.6M
Q4 '232023-12-3160.2M
Q3 '232023-09-3070.8M
Q2 '232023-06-3080.9M
Q1 '232023-03-31-107.9M
Q4 '222022-12-3189.6M
Q3 '222022-09-3076.4M
Q2 '222022-06-3075.8M
Q1 '222022-03-31-104.6M
Q4 '212021-12-3171.9M
Q3 '212021-09-3050.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3081.4M
Q1 '262026-03-3183.1M
Q3 '252025-09-3085.6M
Q2 '252025-06-3085.5M
Q1 '252025-03-3185.4M
Q3 '242024-09-3084.5M
Q2 '242024-06-3083.3M
Q1 '242024-03-3183.3M
Q3 '232023-09-3083M
Q2 '232023-06-3082.7M
Q1 '232023-03-3182.3M
Q3 '222022-09-3082.8M
Q2 '222022-06-3085.6M
Q1 '222022-03-3185.4M
Q3 '212021-09-3086.1M
Q2 '212021-06-3085.9M
Q1 '212021-03-3185.5M
Q4 '202020-12-3185.1M
Q3 '202020-09-3083.9M
Q2 '202020-06-3083.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-302.09
Q1 '262026-03-312.06
Q4 '252025-12-311.94
Q3 '252025-09-301.91
Q2 '252025-06-301.30
Q1 '252025-03-31-1.00
Q4 '242024-12-31-1.19
Q3 '232023-09-301.13
Q2 '232023-06-301.24
Q1 '232023-03-311.22
Q4 '222022-12-310.80
Q3 '222022-09-301.00
Q2 '222022-06-300.99
Q1 '222022-03-311.08
Q4 '212021-12-311.54
Q3 '212021-09-300.22
Q2 '212021-06-30-0.63
Q1 '212021-03-31-9.07
Q4 '202020-12-31-9.50
Q3 '202020-09-30-8.63